CARM1 targeting potentiates IMiD activity: a novel approach to multiple myeloma therapy

ABSTRACT: Advancements in the treatment of multiple myeloma (MM) have resulted in significant improvement in the survival rate for patients <65, however not for patients >65. There is a particular need for improved therapies for this patient population. The protein arginine methyltransferase, CARM1 (coactivator associated arginine methyltransferase 1), is emerging as a potential cancer therapy target and inhibitors have been developed. MM cell lines are particularly dependent on CARM1 for cell survival. Here, we show that CARM1 targeting through a small molecule drug potentiates immunomodulatory drugs (IMiD) treatment in models of MM, likely through synergistic targeting of Aiolos (IKZF3) and MYC expression. Consistent with this, biorational development of a new molecule, 074, comprised of the CARM1 inhibitor, EZM2302, linked to the IMiD pomalidomide led to more potent killing of MM cells than either compound individually. 074 treatment or the combination of CARM1 knockdown (KD) with pomalidomide led to an upregulation of inflammation and interferon signaling pathways and downregulation of MYC signaling. Importantly, 074 reversed IMiD resistance characterized by MYC protein upregulation and cereblon (CRBN) protein downregulation. Taken together, our results demonstrate that dual CARM1/IKZF3-targeting agents represent a promising novel therapeutic strategy for MM and IMiD-resistant disease.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Eric Fischer  

LAB HEAD: Eric Fischer

PROVIDER: PXD046700 | Pride | 2025-05-06

REPOSITORIES: Pride